Abstract:Background: TIM-4, the only TIM protein not expressed on T cells, is found on macrophages and dendritic cells. As an innate immunity-driven local inflammation response, we hypothesized that TIM-4 signaling may play a role in the mechanism of liver IRI. Methods&Results: Unlike in sham controls, the ischemia insult triggered TIM-4 mRNA expression in mouse livers subjected to warm ischemia (90min) and reperfusion (0-24h). Its levels increased progressively, peaking by 6h of reperfusion, and declining at 12-24h. TIM-4 expression correlated with the kinetics of hepatocellular damage (sALT levels), and macrophage infiltration/activation, both peaking at 6h of reperfusion. Indeed, TIM-4 KO or WT (B/6) mice treated with antagonistic TIM-4 mAb (RMT4-53; 0.5 mg i.v. at -1h) were resistant against liver IRI, as shown by sALT levels, hepatic architecture (no edema, vacuolization/necrosis), and Suzuki’s histological score. Unlike in controls, TIM-4 blockade/ablation decreased hepatic CD68+ macrophage sequestration. Although TLR2, TLR4, and TLR9 were all induced in Ig-treated IR-stressed livers, their levels were suppressed in TIM-4 KO groups, along with diminished pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6). To document the function of TIM-4+ macrophages, we have developed a new model of liver IRI in which CD11b-DTR mice were adoptively transferred with syngeneic bone marrow macrophages (BMM; 5×106 cells i.v. at day -1). After DT treatment at day -2 (circulating CD11b <0.2%), CD11b-DTR mice remained uniformly IR-resistant, compared with PBS-controls. Interestingly, unlike WT BMM, which recreated liver IRI after adoptive transfer in CD11b-DTR test mice, infusion of TIM-4-deficient BMM failed to trigger IRI, as shown by diminished sALT levels, well-preserved liver architecture, and decreased Suzuki’s histological score. Of note, consistently heightened TNF-α, IL-1β, and IL-6 levels in CD11b-DTR mice repopulated with TIM-4 proficient (WT) BMM were diminished after infusion of TIM-4 deficient (KO) BMM. Conclusion: This study provides new evidence that: 1) IR-stressed liver macrophages express TIM-4; 2) Disruption of TIM-4 signaling ameliorates liver IRI; and 3) TIM-4 signaling is critically required for macrophage activation in the mechanism of liver IR-damage. Hence, modulation of physiological TIM-4 expression provides the basis for novel therapeutic strategies against organ IRI in transplant recipients.

Targeting TRAF3 Signaling Protects Against Hepatic Ischemia/reperfusions Injury

Tripartite Motif‐Containing 27 Attenuates Liver Ischemia/Reperfusion Injury by Suppressing Transforming Growth Factor β–Activated Kinase 1 (TAK1) by TAK1 Binding Protein 2/3 Degradation

Triiodothyronine Attenuates Hepatic Ischemia/reperfusion Injury in a Partial Hepatectomy Model Through Inhibition of Proinflammatory Cytokines, Transcription Factors, and Adhesion Molecules

C1q/tumor Necrosis Factor-Related Protein-3 Acts As a Target Treating Hepatic Fibrosis

TNFAIP3 Interacting Protein 3 Is an Activator of Hippo‐YAP Signaling Protecting Against Hepatic Ischemia/Reperfusion Injury

KEAP1-NRF2 Complex in Ischemia-Induced Hepatocellular Damage of Mouse Liver Transplants

Recipient T cell TIM-3 and hepatocyte galectin-9 signalling protects mouse liver transplants against ischemia-reperfusion injury.

TRPM2 Mediates Hepatic Ischemia–Reperfusion Injury via Ca <sup>2+</sup> -Induced Mitochondrial Lipid Peroxidation through Increasing ALOX12 Expression

A Role of Microrna‐370 in Hepatic Ischaemia‐reperfusion Injury by Targeting Transforming Growth Factor‐β Receptor II

Horizontal flow of pore fluids

The Role of NLRP3 Inflammasome Activation Pathway of Hepatic Macrophages in Liver Ischemia–Reperfusion Injury

T-Cell Immunoglobulin and Mucin Domain 4 (Tim-4) Signaling in Innate Immune-Mediated Liver Ischemia-Reperfusion Injury (Iri)

TGR5 deficiency aggravates hepatic ischemic/reperfusion injury via inhibiting SIRT3/FOXO3/HIF-1ɑ pathway

CTRP3 alleviates cardiac ischemia/reperfusion injury via LAMP1/JIP2/JNK signaling pathway

miR-194 ameliorates hepatic ischemia/reperfusion injury via targeting PHLDA1 in a TRAF6-dependent manner

Novel Targets and Therapeutic Strategies to Protect Against Hepatic Ischemia Reperfusion Injury

ARRB1 Protects Against Hepatic Ischemia-Reperfusion Injury Via Interaction with TRAF6

METTL3 Deficiency Aggravates Hepatic Ischemia/Reperfusion Injury in Mice by Activating the MAPK Signaling Pathway

Effects of cyproheptadine on symptoms and attitudes in anorexia nervosa.

Mtor Activation Protects Liver from Ischemia/reperfusion‐induced Injury Through NF‐κB Pathway

CTRP3 alleviates myocardial ischemia/reperfusion injury in mice through activating LAMP1/JIP2/JNK pathway